Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 10/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | SELP | P16109 | 3/20 | 0.47 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16070899 | 0.94 | TLR4 (0.52) | TLR4MAPK1CNR1CNR2TRPV1 | |
| SCHEMBL9233216 | 0.93 | MAPK1 (0.60) | TLR4MAPK1LY96CA2CA9 | |
| SCHEMBL16773657 | 0.92 | TLR4 (0.60) | TLR4MAPK1CNR1CNR2TRPV1 | |
| SCHEMBL2791012 | 0.90 | MAPK1 (0.54) | TLR4MAPK1LY96 | |
| SCHEMBL10064893 | 0.90 | MAPK1 (0.54) | TLR4MAPK1LY96 | |
| SCHEMBL16070884 | 0.87 | MAPK1 (0.49) | TLR4MAPK1SELPCA2CA9 | |
| SCHEMBL2741377 | 0.86 | MAPK1 (0.50) | TLR4MAPK1SELPLY96 | |
| SCHEMBL2741376 | 0.86 | MAPK1 (0.50) | TLR4MAPK1SELPLY96 | |
| SCHEMBL16160411 | 0.84 | TLR4 (0.49) | TLR4MAPK1CNR1CNR2TRPV1 | |
| SCHEMBL16160412 | 0.84 | TLR4 (0.49) | TLR4MAPK1CNR1CNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150305333-A1 | USE OF GLUCOSAMINE AMIDES AS PLANT GROWTH AND YIELD ENHANCERS | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150305333-A1 | USE OF GLUCOSAMINE AMIDES AS PLANT GROWTH AND YIELD ENHANCERS | NANS, UGCG, B3GNT2 | TLR4 2036/4885MAPK1 1850/4885CNR1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.